» Articles » PMID: 32104741

Species Distribution and Susceptibility Profiles of Candida Species Isolated from Vulvovaginal Candidiasis, Emergence of C. Lusitaniae

Overview
Journal Curr Med Mycol
Date 2020 Feb 28
PMID 32104741
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: The aim of the current study was to investigate the epidemiology of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), as well as the antifungal susceptibility patterns of species isolates.

Materials And Methods: A cross-sectional study was carried out on 260 women suspected of VVC from February 2017 to January 2018. In order to identify species isolated from the genital tracts, the isolates were subjected to polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) using enzymes and sequencing. Moreover, antifungal susceptibility testing was performed according to the Clinical and Laboratory Standards Institute guidelines (M27-A3).

Results: Out of 250 subjects, 75 (28.8%) patients were affected by VVC, out of whom 15 (20%) cases had RVVC. Among the species, was the most common species (42/95; 44.21%), followed by (18/95; 18.95%), (13/95; 13.69%), (8/95; 8.42%), (6/95; 6.31%), (5/95; 5.26%), (2/95; 2.11%), and (1/95; 1.05%), respectively. Multiple species were observed in 28% (21/75) of the patients. Nystatin showed the narrowest range of minimum inhibitory concentration (MIC) (0.25-16 μg/ml) against all strains, whereas fluconazole (0.063-64 μg/ml) demonstrated the widest MIC range. In the current study, as the second most common causative agent of VVC, was susceptible to all antifungal agents. Furthermore, 61.1% of isolates were inhibited at a concentration of ≤ 2 μg/ml while 38.9% (n=7) of them exhibited fluconazole MICs above the epidemiologic cutoff values (ECV). species showed the highest overall resistance against fluconazole (61.3%), followed by itraconazole (45.2%) and caspofungin (23.7%). All of strains were resistant to itraconazole with a MIC value of ≥ 1 μg/ml; in addition, 87.5% of them were resistant to fluconazole. Moreover, 100% and 87.5% of strains were resistant to caspofungin and fluconazole, respectively.

Conclusion: As the findings revealed, the majority of VVC cases were caused by non- species which were often more resistant to antifungal agents. generally had fluconazole MICs above the ECV. Given the propensity of to develop resistance under drug pressure, antifungals should be administered with caution. The emergence of these species justify the epidemiological surveillance surveys to watch out the distribution of yeast species.

Citing Articles

Reported prevalence and comparison of diagnostic approaches for Candida africana: a systematic review with meta-analysis.

Jonani B, Kasule E, Bwire H, Mboowa G Diagn Progn Res. 2024; 8(1):16.

PMID: 39639364 PMC: 11619109. DOI: 10.1186/s41512-024-00180-6.


Genital-oral transmission of .

Veraldi S, Bortoluzzi P, Germiniasi F, Grancini A Int J STD AIDS. 2024; 36(2):158-160.

PMID: 39471997 PMC: 11773991. DOI: 10.1177/09564624241296582.


Impact of interkingdom microbial interactions in the vaginal tract.

Cohen S, Ost K, Doran K PLoS Pathog. 2024; 20(3):e1012018.

PMID: 38457371 PMC: 10923463. DOI: 10.1371/journal.ppat.1012018.


Species distribution and antifungal susceptibility profiles of yeasts isolated from onychomycosis: a cross-sectional study with insights into emerging species.

Yazdanpanah S, Jabrodini A, Motamedi M, Zomorodian K, Kharazi M, Shabanzadeh S Antonie Van Leeuwenhoek. 2023; 117(1):6.

PMID: 38153531 DOI: 10.1007/s10482-023-01914-0.


Emergence of cryptic species and clades of species complex exhibiting limited susceptibility to antifungals in patients with candidemia.

Francisco E, Ribeiro F, Almeida Junior J, Pedoni D, Matta D, Dolande M Microbiol Spectr. 2023; :e0511522.

PMID: 37698428 PMC: 10580822. DOI: 10.1128/spectrum.05115-22.


References
1.
Reedy J, Floyd A, Heitman J . Mechanistic plasticity of sexual reproduction and meiosis in the Candida pathogenic species complex. Curr Biol. 2009; 19(11):891-9. PMC: 2788334. DOI: 10.1016/j.cub.2009.04.058. View

2.
Mukasa K, Herbert I, Daniel A, Sserunkuma K, Joel B, Frederick B . Antifungal Susceptibility Patterns of Vulvovaginal species among Women Attending Antenatal Clinic at Mbarara Regional Referral Hospital, South Western Uganda. Br Microbiol Res J. 2015; 5(4):322-331. PMC: 4652954. DOI: 10.9734/BMRJ/2015/13804. View

3.
Noori M, Dakhili M, Sepahvand A, Davari N . Evaluation of esterase and hemolysin activities of different species isolated from vulvovaginitis cases in Lorestan Province, Iran. Curr Med Mycol. 2018; 3(4):1-5. PMC: 5917094. DOI: 10.29252/cmm.3.4.1. View

4.
Atkinson B, Lewis R, Kontoyiannis D . Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome. Med Mycol. 2009; 46(6):541-6. DOI: 10.1080/13693780801968571. View

5.
Dovnik A, Golle A, Novak D, Arko D, Takac I . Treatment of vulvovaginal candidiasis: a review of the literature. Acta Dermatovenerol Alp Pannonica Adriat. 2015; 24(1):5-7. DOI: 10.15570/actaapa.2015.2. View